|Home | About | Journals | Submit | Contact Us | Français|
The Trial to Assess Chelation Therapy (TACT) is an NIH-sponsored, randomized, double blind, placebo-controlled, 2×2 factorial clinical trial testing the benefits and risks of 40 infusions of a multi-component Na2EDTA-chelation solution compared with placebo, and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow 1708 patients for an average of approximately 4 years. The primary endpoint is a composite of all cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900 patient substudy will examine quality of life outcomes. The trial is designed to have >85% power to detect a 25% relative reduction in the primary endpoint for each treatment factor. Enrollment began in September 2003 and completed in October 2010.
National surveys consistently show that over one third of adult patients in the U.S. use alternative therapies1,2,3, for which reliable evidence of net benefits is lacking. Chelation therapy with disodium ethylenediaminetetraacetic acid (Na2EDTA), a drug currently without indication in the US4, is one such therapy.
EDTA chelation of divalent and trivalent ions has been postulated to produce a favorable effect on atherosclerotic plaque, questionably leading to reductions in symptoms, improvement in endothelial function and major vascular events5,6,7. Thus, EDTA chelation is sometimes used for the treatment of coronary and peripheral artery disease, and the disodium salt has been favored because of the potential to decalcify atherosclerotic plaque8. There is also ample evidence of potential harm. Disodium EDTA, may cause hypocalcemia and death, particularly when it is infused rapidly9. The available evidence for treatment effects of chelation therapy in patients with coronary heart disease or peripheral arterial disease is mixed, and limited to case series10 and three small trials evaluating11,12,13 surrogate endpoints.
The ongoing use of a therapy with the potential for benefit as well as harm led to the release of a Request for Applications (RFA 01-004, April 2001) by the National Center for Complementary and Alternative Medicine (NCCAM), co-funded by NCCAM and the National Heart, Lung, and Blood Institute (NHLBI) of the US National Institutes of Health.
TACT, ClinicalTrials.gov identifier NCT00044213, is a randomized, double blind, placebo-controlled, 2×2 factorial trial testing the benefits and risks of 40 infusions of a standard multi-component disodium EDTA-chelation solution compared with placebo, and of an oral, high-dose multivitamin and mineral supplement compared with placebo. The primary endpoint is a composite of all cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. This trial is supported by grant number U01 HL92607 from the NHLBI and NCCAM.
The trial uses the components, route, and methods of administration of disodium EDTA chelation recommended by the American College for Advancement in Medicine (ACAM)14, the largest organization of chelating physicians in North America. The ACAM Board approved the final disodium EDTA dosage and frequency of infusions and all vitamin protocols. The authors are solely responsible for the design and conduct of this study, the drafting and editing of the paper, and its final contents.
A grant to conduct the trial was awarded to Mount Sinai Medical Center in August 2002. The US Food and Drug Administration approved the Investigational New Drug application for the Akzo Nobel (Lima, OH, USA) formulation of disodium EDTA chelation in April 2003 (IND # 66,743). The first patient was randomized in September 2003. The trial concluded enrollment of 1708 patients in October 2010. The last TACT follow-up visit will take place in October 2011.
The Clinical Coordinating Center (CCC) is located at Mount Sinai Medical Center, Miami Beach FL. The Duke Clinical Research Institute (Durham, NC) serves as the Data Coordinating Center (DCC), and the Economics and Quality of Life Coordinating Center. The TACT central pharmacy (Accu-Care Services Pharmacy, Miami FL 9/10/2003 TO 6/18/2010, and Universal Arts Pharmacy from 6/28/2010 to the present) has mixed and delivered, to date, over 50,000 bags of blinded chelation solution and the corresponding oral vitamin supplements to clinical sites.
Clinical sites complete TACT investigator and coordinator training. They meet all NIH, FDA, and Office for Human Research Protections requirements for participation in federally-funded studies.
TACT data collection takes place through an Internet-based, electronic data capture system (TrialMaster™, OmniComm Systems, Davie FL). This permits real-time, patient-specific prescription of the EDTA dose of the active chelation solution, based on an individual patient’s estimated glomerular filtration rate (eGFR). An unblinded physician not otherwise involved with the study at the CCC gives patient-specific prescription approval.
Specific steps with regards to training, site visits by the DCC, and TrialMaster programming are taken to assure the integrity of the patient data collected in TACT.
The NIH, FDA, and local or central IRBs oversee TACT. A Data and Safety Monitoring Board (DSMB) reviews unblinded outcome and safety data approximately every 6 months, and recommends whether to continue the trial. The members of the DSMB include experts in clinical trial design and interpretation, bioethics, cardiology, pharmacology, chelation therapy, and biostatistics.
The site investigator documents all adverse events and serious adverse events (SAE) that occur from initiation of study drug through 30 days following the final study infusion. The site investigator assigns causality to each SAE. The DCC Medical Monitor or designee determines which SAEs meet the “unexpected” criteria (not labeled in the Investigator’s Brochure) and makes an independent assessment of causality. A blinded Clinical Events Committee performs clinical event adjudication.
Patients are eligible if they are at least 50 years of age and have had an acute myocardial infarction more than 6 weeks prior to enrollment, and are ineligible if they have abnormal renal function or other exclusions (Tables I and andIIII).
Randomization is carried out on the TACT TrialMaster™ System. Patients are randomly assigned in equal proportions to one of the four treatment arms defined by the 2 × 2 factorial design.
All eligible consenting patients are randomized to receive 40 infusions of either chelation solution (Table III) or placebo, consisting of 500 mL of normal saline and 1.2% dextrose. The first 30 infusions occur weekly. The final 10 infusions may occur between 2 weeks and up to 8 weeks apart. Each patient is also randomized to receive either an oral high-dose vitamin and mineral supplement, or identical-appearing placebo pills (Table IV). The dosing and components of the high-dose oral vitamins were developed with the collaboration of ACAM and represent the typical multi-intervention treatment offered by chelation therapy practitioners. Finally, during the infusion phase of the trial, all study patients receive a daily low-dose regimen consisting of vitamin B6 25 mg, zinc 25 mg, copper 2 mg, manganese 15 mg, and chromium 50 mcg, to prevent depletion by the chelation regimen.
The chelation solution is blinded using a previously piloted method15. The shipped and refrigerated infusion pack contains an ascorbic acid syringe (or ascorbic acid placebo), one syringe with EDTA (or EDTA placebo), and a bag for intravenous infusion with all the other components already mixed (or a bag containing only normal saline if the patient is assigned to the placebo arm). At the time of infusion, the Site Coordinator injects the contents of the syringe into the infusion bag. The placebo oral high-dose vitamins are identical-appearing to the active therapy.
Patients are seen at baseline, and at each of the 40 infusion visits. Following the infusion phase of the trial, patients are contacted quarterly by telephone, have annual clinic visits, and are seen at the end of the trial or at the 5 year followup, whichever occurs first. TACT study procedures recommend evidence-based concomitant care for post-MI patients.
The most important potential adverse events are hypocalcemia and renal toxicity. Nephrotoxicity has been encountered with far higher doses than TACT uses as well as more frequent administration16,17, and in patients with underlying renal disease. Patients with a baseline creatinine >2.0 are excluded from the trial. Renal function is assessed at baseline, and 9 additional times during the infusion regimen. Sites are issued an electronic alert, copied to the CCC, when there is a 25% decrease in estimated GFR, and infusions stop until creatinine levels return to baseline. Infusions are permanently stopped when there is either a doubling of serum creatinine, or an increase to a level of 2.5 mg/dL, whichever is lower. Hematuria and proteinuria are assessed using urine dipstick.
Hypocalcemia due to rapid administration of disodium EDTA is another potentially serious side effect8. Patients receive infusions over a three-hour period and over a longer time-span if the calcium level, corrected for albumin concentration, is low. Short infusions are reported electronically to the site, the CCC, and the DCC.
Hypoglycemia in diabetics is another potential side effect. Diabetics on insulin snack before the infusion, and sites are able to teat hypoglycemia if necessary.
Additional side effects include hypotension, trace metal and vitamin deficiency syndromes, febrile episodes, and heart failure due to fluid overload. During the trial, the patient consent and brochure were modified to include heart failure as a possible adverse event associated with the infusions. The FDA was notified of this finding. The trial also instituted weighing patients prior to all infusions and required a clinical evaluation if the patient had gained 5 lbs or more since the baseline visit to rule out potential progression or new onset of heart failure.
Infusions are delayed in patients whose ALT, AST, alkaline phosphatase or bilirubin double, or total white blood cell count falls below the normal limit. The development of thrombocytopenia to below 100,000 platelets, or a 50% decrease from baseline leads to a delay of infusions until platelet count reverts to normal levels, and an omission of unfractionated heparin from future infusions.
All SAEs are reported to the Data and Safety Monitoring Board, NIH, and FDA on a regular basis. Deaths and unexpected SAEs are reported in an expedited fashion to the above and to the IRBs. Hospitalizations for heart failure are reported to the DSMB and NIH in an expedited fashion.
The primary endpoint is a composite of all cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A key secondary endpoint is the composite of cardiovascular death, non-fatal MI, or non-fatal stroke.
There are 4 other pre-specified secondary endpoints: 1] quality of life; 2] cost-effectiveness of therapy, 3] high sensitivity C-reactive protein, and 4] estimated GFR.
Baseline quality of life data includes eight scales from the Medical Outcomes Study Short Form (SF-36)18, the Duke Activity Status Index (DASI)19, bed and disability day questions from the National Interview Survey20, job class and days lost from work and the Seattle Angina Questionnaire21, the New York Heart Association congestive heart failure class and the Canadian Cardiovascular Society class for angina. The EuroQol22 utility is collected at baseline. A random subset of 900 patients undergoes telephone interviews at 6, 12, and 24 months follow-up. Economic analyses comparing costs between arms will be conducted if either of the experimental therapies demonstrates a reduction in the primary endpoint. The level of C-reactive protein will be compared between treatment groups in 600 patients. We will compare estimated GFR in patients receiving active EDTA treatment compared with those receiving placebo infusions.
TACT originally planned to enroll 2372 patients over 3 years. Difficulties in enrolling the requisite numbers of patients ultimately led to a reduction in the total sample size to 1700 patients, with a counterbalancing extension in median followup to 4 years. The event rates in each control arm of TACT were estimated based on published data on similar post-MI patient populations participating in clinical trials23, namely 20% or higher after 2.5 years of followup. The level of non-compliance with EDTA (or placebo) infusion therapy and oral vitamin (or placebo) expected in TACT was estimated as 7.2% of patients per year, or 22% over 3 years. We also assumed a loss to follow-up rate of up to 3% of patients in the trial. This statistical plan provides 85% power for detecting a 25% relative reduction in the primary endpoint for each treatment.
All major treatment comparisons will be performed according to the principle of intention-to-treat. Statistical comparisons will be performed using two-sided significance tests. The primary statistical assessments will compare EDTA chelation with placebo infusions, and oral high-dose vitamins with oral placebo. The log-rank test24 will be used for the adjusted comparisons of each treatment factor. Cumulative event rates will be calculated according to the Kaplan-Meier method25. Hazard ratios with associated confidence intervals and will be derived from the Cox proportional hazards model26. The Cox model will also be used to assess whether there is an interaction of EDTA chelation therapy with high dose vitamins. Interim treatment comparisons are monitored with the use of 2-sided, symmetric O’Brien-Fleming boundaries generated with the Lan-DeMets alpha-spending function approach to group-sequential testing27,28.
A limited number of pre-specified subgroup analyses of the primary outcome and selected secondary outcomes will test the efficacy of chelation therapy and/or high dose vitamins. Treatment comparisons will be performed within subgroups defined by:
Subgroup differences in treatment effects will be assessed with the Cox model, by testing for interactions between the randomized treatment factor and the specific baseline variables listed above.
National surveys have documented widespread use of CAM by patients across a broad spectrum of diagnoses1,2. ACAM, and other organizations trains chelation practitioners annually. The Centers for Disease Control and Prevention estimate that approximately 111,000 US adults used chelation therapy in 2007 3, a 66% increase since the previous survey in 200229. The need to accumulate sufficient randomized evidence of a CAM therapy such as EDTA chelation goes beyond the need to identify a new therapy for patients with coronary disease. The labeled toxicities, which include renal insufficiency, cardiac arrhythmias, hypocalcemia, hematologic problems, respiratory arrest, and death, must be assessed in the context of a therapy with potential, but unproven benefits. This fair and balanced assessment can be carried out only in the context of a randomized trial.
The interpretation of any benefit or harm of chelation therapy as used in the community would be confounded by the concomitant use of high-dose oral supplements, a common clinical practice. Moreover, the use of high-dose supplements may not be innocuous 30,31,32. Thus, the vitamin-treatment comparison, like the chelation comparison, stands alone as important for the assessment of efficacy, as well as safety.
Besides challenges typical of large multisite trials, TACT was faced with several additional hurdles. Substantial recruitment difficulties led NIH to organize a review of trial progress carried out by a panel of experts in cardiovascular research independent of NIH, of the trial DSMB, and of trial investigators. Despite estimates that trial completion would be delayed several years, this independent committee concluded TACT should continue with a reduced sample size. Concerns about the informed consent process, and about trial conduct at several clinical sites also prompted investigations by OHRP and FDA respectively. Following their reviews, each Federal agency recommended the trial could continue after corrective steps were taken. All sites met NIH, FDA, and Office for Human Research Protections requirements for participation in federally-funded studies, including ethics review by a local or central IRB with a Federal-Wide Assurance. Details on these implementation issues will be presented in a subsequent article.
At this time TACT has finished enrollment, has delivered the final infusions and vitamins, and is expected to present final results in 2012.
TACT has been designed to test whether EDTA chelation therapy and high-dose oral vitamin and mineral therapy offer clinical, quality of life, and economic benefits for patients with a prior MI.
The authors wish to acknowledge the valuable contributions of the following individuals: Ronald Hoffman, MD & Charles Hennekens, MD, DrPh for protocol design, the CCC Project Directors (Ana Mon, MPH, Jacqueline Arciniega, MPH, Jaime Zimmerman MPH, Danielle Hollar PhD), the CCC Trial Managers (Esteban Escolar MD, Faisal Shamshad MD, Pablo Guala MD, Kayvan Amini DO, Steven Hussein MD, Alan Ackermann DO), the Project Managers at the DCC (Sandra Tourt-Uhlig RN MSN, Joyce Good RN CCRC, Lindsay Lambe BA CNMT, Wanda Parker RN MSN, Nancy Clapp-Channing MPH, Diane Minshall-Liu CCRP), the NHLBI team members (Yves Rosenberg MD, Mario Stylaniou PhD, and Erin Iturriaga) and DSMB members (Howard Hodis, MD-Chair, Stephen Buckley, PharmD, Barry Davis, MD, PhD, Theodore Ganiats, MD, Robert Nash, MD, D. George Wyse, MD, PhD and Gail Geller, ScD, MHS) the Project Directors at Omnicomm® Systems (Chris Droz, Brandon Diaz), and the central pharmacy team (Eric M. Alvarez, PharmD, Juan Mora RPh, Marcia Perez), the NCCAM Office of Communication and Outreach (Alyssa Cotler, MPH), the NHLBI Office of Communications (Susan Dambrauskas, NHLBI Press Team Leader), and the Florida Heart Research Foundation for funding the pilot study.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.